An FDA advisory committee’s reconsideration of the benefits and risks of calcitonin drugs used to treat post-menopausal women with osteoporosis has clear implications for future products, but the agency received a mixed view on how to regulate products already approved.
Members of the Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees agreed 20-1 at a March 5...